Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;141(1):86-94.
doi: 10.1016/j.ygyno.2015.12.030.

Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine

Dmitriy Zamarin  1 , Amir A Jazaeri  2
Affiliations
Review

Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine

Dmitriy Zamarin et al. Gynecol Oncol. 2016 Apr.

Abstract

During the past decade significant progress in the understanding of stimulatory and inhibitory signaling pathways in immune cells has reinvigorated the field of immuno-oncology. In this review we outline the current immunotherapy based approaches for the treatment of gynecological cancers, and focus on the emerging clinical data on immune checkpoint inhibitors, adoptive cell therapies, and vaccines. It is anticipated that in the coming years biomarker-guided clinical trials, will provide for a better understanding of the mechanisms of response and resistance to immunotherapy, and guide combination treatment strategies that will extend the benefit from immunotherapy to patients with gynecologic cancers.

Keywords: Cervical cancer; Checkpoint inhibitors; Endometrial cancer; Gynecologic cancers; Immuno-oncology; Immunotherapy; Ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors report no relevant conflicts of interest.

References

    1. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–7. - PubMed
    1. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature. 2005;437:141–6. - PubMed
    1. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8:279–89. - PMC - PubMed
    1. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227–42. - PMC - PubMed
    1. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer research. 2009;69:3077–85. - PMC - PubMed

Publication types